在患有皮质类固醇不耐受性皮质性性病的儿科患者中使用secukinumab治疗:一个病例报告
Wang Liwei1, Qian Yihong1, Tan Fei2
1Skin & Cosmetic Research Department, Skin Disease Hospital of Tongji University, Shanghai, China.
Frontiers in medicine
|October 20, 2025
概括
在儿童中治疗皮肤病 (PG) 治疗可能具有挑战性. 一种IL-17A抑制剂Secukinumab对皮质类固醇不耐受的儿科PG病例显示出希望,提供了显著的改善.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 皮肤病 (Pyoderma gangrenosum,简称PG) 是一种罕见的,痛苦的中性恋性皮肤病.
- 病原发生涉及遗传,自身免疫和中性粒细胞疾病.
- IL-17抑制剂显示出潜力,但在PG中反应率有限.
研究的目的:
- 报告一个儿科病例的皮质类固醇不耐受PG.
- 在这种情况下,评估secukinumab (一种IL-17A抑制剂) 的疗效.
主要方法:
- 一名患有皮质类固醇不耐受性PG的儿科患者接受了secukinumab的治疗.
- 评估了临床改善.
主要成果:
- 患者在接受sequukinumab治疗后取得了显著的改善.
- 塞库金努马布有效地管理了耐火儿科PG.
结论:
- 塞库金纽马布是儿科PG的潜在治疗选择.
- 这一案例为使用IL-17A抑制剂管理耐火儿科PG提供了洞察力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Inflammatory Bowel Disease II: Crohn's Disease
947
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
947
Drugs for Treatment of Ulcerative Colitis in IBD
452
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
452


